2365 Nanoliposomal irinotecan (MM-398, nal-IRI) population pharmacokinetics (PK) and its association with efficacy and safety in patients with solid tumors based on the phase 3 study NAPOLI-1 and five phase 1 and 2 studies. (September 2015) - Ma, W.W.; Chung, I.; Lang, I.; Csõszi, T.; Wenczl, M.W.; Cubillo, A.; Chen, J.; Wong, M.; Park, J.O.; Kim, J.S.; Rau, K.M.; Melichar, B.; et al.